Jakob W. Gotfredsen

No más puestos en curso

Health Technology

Consumer Services

Commercial Services

Perfil

Jakob W.
Gotfredsen is the founder of Neurokey A, which was founded in 2007.
He held the title of Chief Business Officer from 2009 to 2010.
In 2004, he worked as a Product Manager at Roche Pharmaceuticals, Inc. until 2005.
Dr. Gotfredsen earned an MBA from the University of Copenhagen.

Antiguos cargos conocidos de Jakob W. Gotfredsen.

Empresas	Cargo	Fin
Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	Fundador	30/07/2010
Roche Pharmaceuticals, Inc. Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ.	Corporate Officer/Principal	01/01/2005

Ver el detalle de la experiencia de Jakob W. Gotfredsen.

Formación de Jakob W. Gotfredsen.

University of Copenhagen

Masters Business Admin

Experiencias
Funciones ocupadas

Activas

Inactivas

Empresas cotizadas

Empresas privadas

Ver el detalle de la experiencia de Jakob W. Gotfredsen.

Relaciones

Relaciones de 1er grado

Empresas vinculadas al 1er grado

Hombre

Mujer

Administradores

Ejecutivos

Consultar la red personal

Empresas relacionadas

Empresas privadas	2
Neurokey A/S Neurokey A/S Pharmaceuticals: MajorHealth Technology Neurokey wants to become a leading drug development company in the critical care field. The drugs under development will one day help countless patients suffering from the effects of debilitating and potentially fatal cardiovascular and neurological; diseases. Neurokey will be first to market with reliable efficient and easily administered medication that will increase the survival rate for these patients and dramatically minimize the risk of permanent neurological damage.	Health Technology
Roche Pharmaceuticals, Inc. Roche Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ.	Commercial Services